
Paolo Tarantino, MD, PhD, and Ying Fan, MD, compare breast cancer care in the US and China and discuss HORIZON-Breast06 and PANKU-Breast01.

Paolo Tarantino, MD, PhD, and Ying Fan, MD, compare breast cancer care in the US and China and discuss HORIZON-Breast06 and PANKU-Breast01.

Li Zhang, MD, discusses OptiTROP-Lung04 and PANKU-Lung01, choosing between sac-TMT and iza-bren, and ADC practice in China and the US.

Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.

Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.

Floor Backes, MD, discusses BEHOLD-1 data for the B7-H4–directed ADC mocertatug rezetecan in platinum-resistant ovarian cancer.

Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.

Experts break down key melanoma data and trends from the 2026 ESMO Congress.

Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.

Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.

Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.

Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.

James J. Harding, MD, and Jian Zhou, MD, PhD, compare first-line biliary tract cancer care in the US and China and discuss HARMONi-GI1.

Pasi A. Jänne, MD, PhD, and Yi-Long Wu, MD, FACS, compare first-line EGFR-mutated NSCLC care in the US and China and discuss SAFFRON and SANOVO.

IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.

Prior immune checkpoint inhibitor exposure raised mucocutaneous adverse effect risk, particularly dermatitis, with lirafugratinib in FGFR2-altered tumors.

Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.

Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.

INCB161734 plus chemotherapy was tolerable and elicited responses in updated data from a trial of patients with KRAS G12D–mutated pancreatic cancer.

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.

Izalontamab brengitecan improved progression-free survival vs chemotherapy in EGFR-mutated lung cancer after a third-generation EGFR inhibitor.

Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.

KEYNOTE-412 ctDNA data tie early clearance to longer survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.

Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.

Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.

Risvutatug rezetecan delayed progression vs gemcitabine and docetaxel in patients with osteosarcoma after 2 or more prior systemic therapies.

Paul L. Swiecicki, MD, discusses first-line amivantamab plus pembrolizumab and carboplatin in recurrent/metastatic head and neck cancer.

Georgina V. Long, AO, BSc, PhD, MBBS, discusses phase 3 INTerpath-001 data for adjuvant intismeran autogene plus pembrolizumab in melanoma.